Abstract
Aim: To assess the reduction in estimated cardiovascular disease (e-CVD) risk after multifactorial treatment for 6 months and follow this change during the next 3-years. Patients-Methods: This prospective, randomized, target driven study included 1,123 subjects (512/611 men/women, aged 45-65 years) with metabolic syndrome (MetS) without diabetes or CVD referred to specialist outpatient clinics. Patients were randomized to two treatment groups: group A with low density lipoprotein cholesterol (LDL-C) target of > 100 mg/dl and group B with a target of < 130 mg/dl. Atorvastatin was used in both groups on top of optimal multifactorial treatment, (quinapril, amlodipine, hydrochlorothiazide for hypertension, metformin for impaired fasting glucose, and orlistat for obesity). The e-CVD risk was calculated using the Framingham, the PROCAM and Reynolds equations. Results: Reductions in e-CVD risk at 6 months were > 50%in all patients, but were superior in group A and in women. Reductions were even greater during the next 3-years and were mainly attributed to changes in lipid profile. Actual CVD events were 1 in group A and 13 in group B; p=0.0012. Conclusions: Attaining the treatment target of LDL-C < 100 mg/dl within multifactorial treatment of MetS by expert clinics, is achievable and beneficial even in patients without diabetes or known CVD. This induces a considerable e-CVD risk reduction in MetS patients. Actual CVD events were negligible, suggesting that e-CVD risk overestimates actual CVD risk in MetS, at least in patients achieving LDL-C < 100 mg/dl [ClinicalTrials.gov ID: NCT00416741].
Keywords: Metabolic syndrome, cardiovascular disease risk, atorvastatin, multifactorial treatment, Framingham, PROCAM, Reynold's, actual events, obesity, low density lipoprotein cholesterol
Current Vascular Pharmacology
Title: Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women
Volume: 9 Issue: 6
Author(s): Vassilios G. Athyros, Emmanouel Ganotakis, Genovefa D. Kolovou, Vassilios Nicolaou, Apostolos Achimastos, Eleni Bilianou, Theodore Alexandrides, Asterios Karagiannis, Konstantinos Paletas, Evangelos N. Liberopoulos, Konstantinos Tziomalos, Dimitrios Petridis, Anna Kakafika, Moses S. Elisaf and Dimitri P. Mikhailidis
Affiliation:
Keywords: Metabolic syndrome, cardiovascular disease risk, atorvastatin, multifactorial treatment, Framingham, PROCAM, Reynold's, actual events, obesity, low density lipoprotein cholesterol
Abstract: Aim: To assess the reduction in estimated cardiovascular disease (e-CVD) risk after multifactorial treatment for 6 months and follow this change during the next 3-years. Patients-Methods: This prospective, randomized, target driven study included 1,123 subjects (512/611 men/women, aged 45-65 years) with metabolic syndrome (MetS) without diabetes or CVD referred to specialist outpatient clinics. Patients were randomized to two treatment groups: group A with low density lipoprotein cholesterol (LDL-C) target of > 100 mg/dl and group B with a target of < 130 mg/dl. Atorvastatin was used in both groups on top of optimal multifactorial treatment, (quinapril, amlodipine, hydrochlorothiazide for hypertension, metformin for impaired fasting glucose, and orlistat for obesity). The e-CVD risk was calculated using the Framingham, the PROCAM and Reynolds equations. Results: Reductions in e-CVD risk at 6 months were > 50%in all patients, but were superior in group A and in women. Reductions were even greater during the next 3-years and were mainly attributed to changes in lipid profile. Actual CVD events were 1 in group A and 13 in group B; p=0.0012. Conclusions: Attaining the treatment target of LDL-C < 100 mg/dl within multifactorial treatment of MetS by expert clinics, is achievable and beneficial even in patients without diabetes or known CVD. This induces a considerable e-CVD risk reduction in MetS patients. Actual CVD events were negligible, suggesting that e-CVD risk overestimates actual CVD risk in MetS, at least in patients achieving LDL-C < 100 mg/dl [ClinicalTrials.gov ID: NCT00416741].
Export Options
About this article
Cite this article as:
G. Athyros Vassilios, Ganotakis Emmanouel, D. Kolovou Genovefa, Nicolaou Vassilios, Achimastos Apostolos, Bilianou Eleni, Alexandrides Theodore, Karagiannis Asterios, Paletas Konstantinos, N. Liberopoulos Evangelos, Tziomalos Konstantinos, Petridis Dimitrios, Kakafika Anna, S. Elisaf Moses and P. Mikhailidis Dimitri, Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women, Current Vascular Pharmacology 2011; 9 (6) . https://dx.doi.org/10.2174/157016111797484080
DOI https://dx.doi.org/10.2174/157016111797484080 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Resolution of Type 2 Diabetes with Reduction in Body Mass Index Using Meal Replacement Based Weight Loss
Vascular Disease Prevention (Discontinued) Scutellarin Attenuates Microglia-Mediated Neuroinflammation and Promotes Astrogliosis in Cerebral Ischemia - A Therapeutic Consideration
Current Medicinal Chemistry Port-a-Patch and Patchliner: High Fidelity Electrophysiology for Secondary Screening and Safety Pharmacology
Combinatorial Chemistry & High Throughput Screening Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology The Role of Tai Chi in Mental Health Management—Lessons Learned from Clinical Trials
Reviews on Recent Clinical Trials Effects of Transcutaneous Electrical Nerve Stimulation in Autonomic Nervous System of Hypertensive Patients: A Randomized Controlled Trial
Current Hypertension Reviews Antioxidant Activity of Two Wild Edible Mushrooms (Morchella vulgaris and Morchella esculanta) from North Turkey
Combinatorial Chemistry & High Throughput Screening Endothelin-1 and Endothelin Converting Enzyme-1 in Human Atherosclerosis - Novel Targets for Pharmacotherapy in Atherosclerosis
Current Vascular Pharmacology Use of BNP and CRP as Biomarkers in Assessing Cardiovascular Disease:Diagnosis Versus Risk
Current Vascular Pharmacology Development of a Triggered Nocturnal Blood Pressure Monitoring which Detects Nighttime Blood Pressure Surges in Sleep Apnea Syndrome
Current Hypertension Reviews Conference Proceedings: Second International Conference on Novel Psychoactive Substances (NPS) Swansea, UK; September 12-13th, 2013
Current Drug Abuse Reviews Renal Injury Following Intravitreal Anti-VEGF Administration in Diabetic Patients with Proliferative Diabetic Retinopathy and Chronic Kidney Disease - A Possible Side Effect?
Current Drug Safety Is Hyperhomocyst(e)inemia A Humoral Predictor of Coronary Heart Disease?
Current Pharmaceutical Design Angiotensin Peptides as AT2 Receptor Agonists
Current Protein & Peptide Science Caffeine and Suicide: A Systematic Review
CNS & Neurological Disorders - Drug Targets Intracranial Non-traumatic Aneurysms in Children and Adolescents
Current Pediatric Reviews Current and Emerging Therapies in Neuroendocrine Tumors: Impact of Genetic Targets on Clinical Outcomes
Clinical Cancer Drugs Resveratrol Improves Cardiovascular Function in DOCA-Salt Hypertensive Rats
Current Pharmaceutical Biotechnology Effect of Long Chain n-3 PUFA on Endothelial Activation, Endothelial Function and Atheromatous Plaque Stability
Current Nutrition & Food Science Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials